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Determination of acidity constants at 37 ºC through the internal 
standard capillary electrophoresis (IS-CE) method: internal 
standards and application to polyprotic drugs 
Leo Lebanov a, Elisabet Fuguet a,b, Javier M. Melo a and Martí Rosés *a 
This work provides the pKa at the biorelevant temperature of 37 ºC for a set of compounds proposed as internal standards 
for the internal standard capillary electrophoresis (IS-CE) method. This is a high throughput method that allows the 
determination of the acidity constants of compounds in a short time, avoiding the exact measurement of the pH of the 
buffers used. pH electrode calibration at 37 ºC can be avoided too. 
In order to anchor the pKa values obtained through the IS-CE method in the pH scale, the acidity constant at 37 ºC of some 
of the standards has been determined also by the reference potentiometric method.  In general, a decrease in the pKa value 
is observed when changing from 25 to 37 ºC, and the magnitude of the change depends on the nature of the compounds. 
Once the pKa values at 37 ºC of the internal standards have been established, the method is applied to the determination of 
the acidity constants of seven polyprotic (5 diprotic and 2 triprotic) drugs. The obtained mobility-pH profiles show well 
defined curves, and the fits provide precise pKa values. Due to the lack of reference data at 37 ºC only the pKas of labetalol 
can be compared to values from literature, and a very good agreement is observed. 
Introduction 
In the past decades, pharmaceutical industry has undergone 
considerable changes due to application of many cutting-edge 
technologies such as combinatorial chemistry, high throughput 
screening, and robotics, and all these new technologies have 
lead to the possibility to synthetize millions of compounds for 
a high number of different health conditions and diseases. The 
drug discovery process is very complex, expensive, and time-
consuming; in average, it takes from 10 to 15 years from the 
discovery of a new compound until the new drug is released to 
the market. The development of better screening methods for 
the evaluation of physicochemical properties of candidate 
compounds at the early stage of the drug discovery process 
can reduce time, decrease expenses, and diminish the number 
of failures in the late stage of drug development. Therefore, 
there is a great need for high-throughput screening methods 
for a rapid determination of physicochemical properties of 
candidate drug compounds.1-3 
One of the properties that affects the pharmaceutical potential 
of a compound, among others, is the acidity constant. The 
acidity constant determines the degree of ionization of the 
compound, which has impact on its solubility, dissolution rate, 
absorption across biological membranes (lipophilicity and 
permeability), distribution to the site of action, renal 
elimination, interaction with efflux systems, metabolism, 
protein binding, and receptor interactions.2,4-5 Nonetheless, 
most of the acidity constants are determined at 25 °C or at 
room temperature, which usually can range from 15 to 30 °C, 
instead of at 37 ºC, the common human biorelevant 
temperature. Accurate determinations of the pKa values at 37 
°C is important for all drugs introduced orally, intramuscularly 
or any other way in which candidate compound should be 
absorbed, distributed, metabolized or excreted at the normal 
body temperature. Acidity constant, pKa in its logarithmic 
form, depends on temperature (T), and many studies 
demonstrate that change of pKa value due to temperature 
depends on the nature of the functional groups of the 
compounds. Whereas simple carboxylic acids have nearly the 
same pKa value at 25 and 37 °C, the pKa values of some bases 
or phenols show an important temperature dependence.5-10 
For example, quetiapine, a basic anti-psychotic drug, with pKa1 
= 2.27 and pKa2 = 7.30 at 25 ºC11 changes its pKa values to 3.56 
and 6.38 at 37 ºC5, respectively. Although the variation of the 
second pKa is not as big as for the first pKa value, its proximity 
to the physiological pH of 7.4 makes accurate determination of 
pKa value even more important. Thus, the ionization degree of 
quetiapine at physiological conditions of pH will be lower at 
37ºC than at 25 ºC, fact that can lead to wrong biodisponibility 
conclusions if the considered pKa values are the ones at 25ºC.  
This work is focused on the use of the internal standard 
capillary electrophoresis method (IS-CE) for the determination 
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of pKa values at 37 ºC. CE has several advantages compared to 
other methods for the determination of acidity constants. It is 
a highly automated technique that requires small amounts of 
compounds and where high purity is not required due to the  
separation performed inside the capillary.12-19 The IS-CE 
method is based on the use of an internal standard (i.e. a 
compound with known pKa) to measure the pH inside the 
capillary. This is obtained from the pKa value of the IS and the 
ratio of mobilities of the pure ionic form of the IS, and the 
mobility at a pH where it is partially ionized. Once the pH is 
known, the ratio of mobilities of the test compound (fully and 
partially ionized) is used to determine its pKa.20,21 Compared to 
the classical CE method for determination of acidity constants, 
the IS-CE is much faster, and it does not require a previous 
exact measurement of the pH value of the buffer, since the pH 
is measured in situ in the capillary under the exact conditions 
of analysis. This is especially relevant in measurements at a 
given temperature, since the calibration of the electrodic 
system used to measure the pH of the buffers at the working 
temperature can be avoided. Moreover, previous works have 
demonstrated that if the IS and the analyte behave in a similar 
way, possible alterations in the experimental conditions that 
may affect the mobilities of the test compound (as for example 
Joule effect) can be compensated by the IS.6,22 On the 
contrary, in the classical CE method any alteration of the 
mobility of the analyte leads to a direct error in the pKa 
determination.14 
The IS-CE method has been well established for the 
determination of pKa values of all types of acid-base 
compounds at 25 ºC. Nevertheless, there is a lack of pKa values 
for internal standards at 37 ºC. The main purpose of this work 
is, therefore, to establish the pKa values at 37 ºC for a 
reference set of internal standards in order to make this high-
throughput method applicable to the characterization of drugs 
at the human biorelevant temperature. 
 
Theory 
For an ionizable acid–base compound, the electrophoretic 
mobility depends on the degree (or degrees) of ionization of 
the compound. Thus, the general acid–base equilibria for a 
monoprotic species, HXz, can be expressed as: 
 
HXz   Xz-1 + H+   𝐩𝐊𝐚
′ = 𝐩𝐇 − 𝐥𝐨𝐠
[𝐗𝐳−𝟏]
[𝐇𝐗𝐳]
               (1) 
 
where z is the charge number of the protonated species and 
pKa’ the logarithmic form of the mixed acidity constant (at a 
given ionic strength, as well as temperature and solvent).23,24  
The µep, also called the effective mobility (µeff), of a 
monoprotic compound can be expressed as a function of the 
pKa’ of the species and the pH of the background electrolyte 
through the following general equation13: 
 
𝛍𝐞𝐟𝐟 =




′                    (2) 
where  𝛍𝐇𝐗𝐳 and 𝛍𝐗𝐳−𝟏are the actual ionic electrophoretic 
mobilities of the subscripted species. 
In the IS-CE method, the use of an IS allows direct calculation 
of the pH of the buffered solution inside the capillary. This 
value is then used to calculate pKa’ of the compound being 
studied. 
For example, for a neutral acid used as the IS, where z is 0, the 






              (3) 
 
where 𝛍𝐞𝐟𝐟(𝐈𝐒)is the effective mobility and 𝛍𝐈𝐒−the actual ionic  
mobility (mobility of the fully charged negative species) of the 
IS. The term corresponding to the uncharged species, 𝛍𝐇𝐗, has 
zero mobility and is removed from Eq 2. Since 𝐩𝐊𝐚(𝐈𝐒)
′  of the IS 
is well known, only two runs at two different pH values are 
needed to calculate the pH: the first where the pH is in the 
range pKa ± 1, in order to calculate the effective mobility; and a 
second in which it is completely ionized to calculate the actual 
ionic mobility. Therefore, although a buffer could experiment 
pKa shifts due to temperature, the provided pH inside the 
capillary can be known by the relation of mobilities and pKa of 
the IS. 
Once the pH inside the capillary is known, the acidity constant 
of the test compound (TC) can be calculated by rearranging Eq. 
2 again:  
 
𝐩𝐊𝐚(𝐓𝐂)
′ = 𝐩𝐇 − 𝐥𝐨𝐠
𝛍𝐇𝐗𝐳  − 𝛍𝐞𝐟𝐟(𝐓𝐂)
𝛍𝐞𝐟𝐟(𝐓𝐂) − 𝛍𝐗𝐳−𝟏
                   (4) 
 
where 𝛍𝐇𝐗𝐳and 𝛍𝐗𝐳−𝟏refer to the actual ionic mobilities of the 
fully charged z and z-1 species of the TC. 
In these equations, 𝐩𝐊𝐚(𝐓𝐂)
′ is related to the thermodynamic 
pKa by the activity coefficients, usually calculated by means of 
the Debye-Hückel equation (Eq. 5)21:  
 
 − 𝒍𝒐𝒈 𝜸 =
𝑨𝒛𝟐√𝑰
𝟏+𝑩𝒂√𝑰
                       (5) 
 
I is the ionic strength of the buffer solutions (0.05 M in this 
work), A and B depend on the solvent relative permittivity  and 
temperature (their values are 0.523 and 0.331, respectively, in 
water at 37 ºC), z is the charge number of the ion, and a is the 
hydrated radius of the ion. The value of a depends on the 
hydrated ion, although a value of 4.5 Å (value for hydrogen 
ion) is commonly taken for most ions. This equation is valid for 
ionic strength values lower than 0.2 M. Activity coefficients of 
neutral species (z = 0) are assumed to be unity. 
In case of polyprotic compounds, equation 2 becomes 
equation 6: 
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𝝁𝒆𝒇𝒇 =
𝝁𝑯𝒏𝑿𝒛













                   (6) 
 
This is a general expression that relates effective mobility and 
pH for any type of acid-base compound.  
Electrophoretic mobility values are calculated through the 
migration times of the analyte (tm) and the electroosmotic flow 











)                       (7) 
 
where LT and LD are the total and effective capillary length, 
respectively, and V is the applied voltage. Mobilities obtained 
in this way can be directly used only in absence of Joule 
heating effect, which causes an increase of temperature inside 
the capillary above the temperature of the capillary coolant. 
Otherwise, temperature corrections of measured mobilities 




Apparatus and conditions. 
CE determinations were performed in a P/ACE MDQ Beckman 
instrument (Palo Alto, CA, USA) equipped with a diode-array 
spectrophotometric detector. A fused-silica capillary of 50 μm 
i.d. and 375 μm o.d. from Polymicro Technologies (Phoenix, 
AZ, USA) was used. Capillary had a total length of 35.2 cm, and 
an effective length of 25.0 cm. Samples were injected at a 
hydrodynamic pressure of 2068 Pa (0.3 p.s.i.) during 2.0 s. 
Separation was performed applying a pressure of 3447 Pa (0.5 
p.s.i.) and a voltage of 20 kV. The absence of Joule effect at 
these separation conditions has been tested for each of the 
used buffers, by checking the linearity between the applied 
voltage and the generated current according Ohm’s law. 
Detection was carried out at 214, 254 and 280 nm with full 
spectra captured from 190 until 300nm. Capillary together 
with sample tray were thermostated at 37 °C (± 0.1 ºC). Under 
these conditions electrophoretic runs duration was under 5 
minutes in most of the buffers.  
Potentiometric pKa determinations were performed in an 888 
Titrando potentiometer from Metrohm (Herisau, Switzerland), 
equipped with a combined pH electrode and a burette also 
from Metrohm, a tempering beaker, and a temperature-
controlled water bath (J. P. Selecta, Abrera, Spain).   
 
Reagents and materials. 
Sodium hydroxide (0.5M TitrisolTM) and hydrochloric acid (1M 
TitrisolTM), dimethyl sulfoxide (>99.8%), and sodium 
dihydrogen phosphate monohydrate (>99%) were from Merck 
(Darmstadt, Germany). Methanol (HPLC grade) was from 
Thermo Fischer Scientific (Waltham, MA, USA). Sodium acetate 
anhydrous (>99.6%) was from Baker (Center Valley, PA, USA). 
Potassium hydrogen phthalate (>99.9%), BisTris (2,2-
Bis(hydroxymethyl)-2,2’,2”-nitrilotriethanol) (>99%), Tris 
(Tris(hydroxymethyl) aminomethane) (>99.9%),  CHES 
(2(cyclohexylamino)ethanesulfonic acid) (>99%), and CAPS (3-
(cyclohexylamino)-1-propanesulfonic acid) (>98%) were from 
Sigma-Aldrich (St Louis, MO, USA). Water was purified by a 
Milli-Q plus system from Millipore (Bedford, MA, USA), with a 
resistivity of 18.2 M cm.  
All internal standards and drugs used for the determinations 
were obtained from Sigma-Aldrich, Scharlab (Sentmenat, 
Spain), Merck, Panreac (Castellar del Vallès, Spain), Carlo Erba 
(Milano, Italy), and J. T. Baker with purity above 98%. 
 
Procedures. 
CE capillary conditioning. Capillary conditioning methodology 
was reported previously.21 Briefly, before the first use it was 
conditioned with 1M NaOH, water and the running buffer; 
when the buffer was changed it was rinsed with water and the 
new buffer; and between runs it was rinsed for 3 minutes with 
the running buffer. At the end of the working session the 
capillary was flushed with water. 
 
Preparation of buffers and solutes for CE analysis. Buffer 
solutions covering practically all the useful pH range (from 2.0 
to 12.0 separated at intervals of 0.5 pH units) were prepared 
at the approximate pH and 50 mM ionic strength as described 
elsewhere.21 
Stock solutions of test compounds and ISs were prepared at a 
concentration of 1 mg mL-1 and 2% v/v of DMSO was added as 
electroosmotic flow (EOF) marker. They were diluted in water 
or in a methanol/water mixture (when they were not soluble 
in water itself). Afterwards, a 1/10 dilution of the stock 
solution in water was prepared for injection (100 mg L-1, 0.2% 
v/v DMSO). Internal standards and test compounds were 
stored at 4ºC until used. All the samples and buffers were 
filtered through a nylon mesh 0.45 µm porous size (Whatman, 
Maidstone, UK). 
 
Potentiometric determination of pKa values. 30 mL of an 
approximately 0.005 M aqueous solution of the IS were placed 
in the thermostated beaker for the titration. Once the solution 
had reached 37 ºC, the titration was performed using 0.1 M 
sodium hydroxide or 0.1 M hydrochloric acid, depending on 
the nature of the IS from pH 2 to pH 12, or vice versa. All 
solutions (titrands and titrants) were prepared with boiled 
water. 0.1M sodium hydroxide solution was previously 
standardized with potassium hydrogen phthalate. 0.1 M 
hydrochloric acid solution was standardized using Tris as 
primary standard. The potentiometric system was calibrated 
with standard reference solutions at pH 2, 4, 7, and 9 at 37 ºC. 
pKa was calculated through the titration data, taking into 
account the mass and charge balances of the species in 
equilibrium. Activity corrections at each titration point were 
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done through the activity coefficients, which were calculated 
through the Debye-Hückel equation. 
 
Data analysis. 
Table Curve 2D from Systat Software Inc. (San Jose, CA, USA) 
was used to fit the mobility – pH curves of polyprotic drugs. 
Other data calculations were performed through Excel 2010 
from Microsoft (Redmond, WA, USA). 
 
Results and discussion 
 
Determination of the pKa at 37 ºC for the set of internal standards. 
In order to establish IS-CE as a high-throughput method for 
determination of pKa values at 37 °C it is necessary to precisely 
determine pKa values of internal standards at this 
temperature. For this purpose, the previously established set 
of 23 monoprotic acids and 22 monoprotic bases22,27 has been 
used. These compounds have different chemical properties 
and cover the most useful pH range in CE. Table 1 lists the set
 
 
Table 1 pKa values for the set of internal standards. Standard deviations are shown in parentheses. 
Internal Standards pKa 25 ºC22,27 N Reference pKa 37 ºC IS-CE pKa 37 ºC 
2-Chlorobenzoic acid (A) 2.84 (0.02) 6  2.79 (0.01) 
2,6-Dibromo-4-nitrophenol (A) 3.31 (0.03) 7  3.24 (0.03) 
4-Nitrobenzoic acid (A) 3.37 (0.01) 7 3.4428 3.27 (0.04) 
2,6-Dinitrophenol (A) 3.69 (0.01) 7  3.57 (0.04) 
3-Bromobenzoic acid (A) 3.79 (0.02) 6  3.71 (0.05) 
2,4-Dinitrophenol (A) 4.12 (0.02)  8  3.89 (0.07) 
Benzoic acid (A) 4.22 (0.03) 18 4.245 4.07 (0.07) 
Ibuprofen (A) 4.49 (0.02) 24 4.5129 4.37 (0.06) 
Aniline (B) 4.63 (0.02) 14 4.41 (0.03) 4.53 (0.05) 
4-tert-Butylaniline (B) 4.93 (0.01) 22  4.56 (0.07) 
Quinoline (B) 4.93 (0.01) 14 4.73 (0.02) 4.86 (0.03) 
Warfarin (A) 5.17 (0.04) 11  4.79 (0.06) 
N,N-Dimethyl-N-phenylamine (B) 5.17 (0.02) 6  5.32 (0.12) 
Pyridine (B) 5.28 (0.01) 7 5.0930 5.14 (0.04) 
2,5-Dinitrophenol (A) 5.30 (0.05) 11  5.05 (0.06) 
Sulfacetamide (B) 5.42 (0.05) 14  5.25 (0.05) 
Acridine (B) 5.55 (0.06) 9 5.0131 5.37 (0.07) 
4-tert-Butylpyridine (B) 6.03 (0.03) 13  5.92 (0.06) 
2,4,6-Tribromophenol (A) 6.04 (0.08) 13  5.88 (0.05) 
Papaverine (B) 6.41 (0.07) 8 6.2232 6.32 (0.04) 
2,4-Lutidine (B) 6.81 (0.05) 19  6.66 (0.06) 
Trazodone (B) 6.84 (0.05) 11  6.69 (0.04) 
Pilocarpine (B) 7.08 (0.02) 12 6.68 (0.01) 6.85 (0.03) 
4-Nitrophenol (A) 7.09 (0.05) 16 7.08 (0.01) 6.82 (0.06) 
Vanillin (A) 7.36 (0.06) 21  7.16 (0.05) 
2,4,6-Trimethylpyridine (B) 7.51 (0.03) 10 7.16 (0.02) 7.22 (0.07) 
Phenobarbital (A) 7.53 (0.04) 22  7.17 (0.05) 
4-Hydroxybenzaldehyde (A) 7.61 (0.04) 10  7.35 (0.05) 
Lidocaine (B) 7.93 (0.01) 14 7.56 (0.01) 7.78 (0.05) 
3,5-Dichlorophenol (A) 8.18 (0.04) 11 8.11 (0.01) 7.92 (0.05) 
Bupivacaine (B) 8.19 (0.03) 10 7.9733 7.96 (0.07) 
Methylparaben (A) 8.35 (0.03) 16 8.21 (0.01) 8.14 (0.06) 
2-Chlorophenol (A) 8.50 (0.04) 15  8.22 (0.06) 
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of internal standards, together with their thermodynamic pKa 
values at 25 ºC.  
A similar approach as the one used at 25 ºC has been applied 
to determine the new pKa values.22,27 Compounds with pKa 
values differing less than one unit have been paired, and the 
roles of test compound and internal standard assigned. For 
this initial experimental design, pKa values at 25 ºC have been 
used when reference data at 37 ºC (Reference pKa 37 ºC in 
Table 1) are not available. Then, each pair has been injected 
twice in the system at 37 ºC. Firstly, using a buffer at a pH 
value where both compounds are partially ionized to obtain 
the effective mobilities. Secondly, in a buffer at a pH value 
where they are totally ionized, to obtain the actual ionic 
mobilities. In case of pairs of different acid-base nature, actual 
ionic mobilities have been obtained at two pH values (2.0 for 
acids and 12.0 for bases). In several instances the same pair 
has been injected at different pH values for the effective 
mobility determination, which rises the number of 
independent experiments (N) for each compound.  
Once mobilities are calculated, Eq. 4 has been applied to each 
pair. To calculate the pKa of the test compound, obtained 
mobility data and the pKa at 25 ºC (or at 37 ºC when possible) 
of the compound used as internal standard have been used. In 
this way, N new pKa values have been obtained for a given 
compound of the set. The average of these N pKas provides a 
new value to start the iterative process, in which the same 
electrophoretic data is used, but the pKas of the ISs are 
changed by the averaged values. The process has been 
repeated four times, until the differences between consecutive 
averaged pKas has been 0.02 pKa units or less. Once the 
iteration process has finished, boxplots have been used to 
identify possible outliers within the N pKa values obtained for a 
same compound. Tukey’s criterium has been used to remove 
the outliers. 
Next step is to anchor the pKa scale by comparison of the 
obtained pKa values to the known reference values. As 
accurate literature pKa data at 37 ºC was scarce for the set of 
compounds used in this work, potentiometric determinations 
at 37 ºC have been performed for some of the compounds in 
order to widen the available reference data. A linear trend is 
observed when the raw CE data is compared to the 
potentiometric data, according to Eq. 8: 
 
pKa,IS-CE,raw = 0.165(0.140) + 0.986(0.019) pKa,Ref        (8) 
n= 21; SD = 0.170; F = 2925 
 
here pKa,IS-CE raw is the pKa obtained through the electrophoretic 
method just after the refinement process, pKa,Ref is the pKa 
determined potentiometrically or obtained from the literature, 
n is the number of compounds used for the correlation, SD is 
the standard deviation of the correlation, and F is the Fisher F 
parameter. 
This correlation indicates that both set of values are 
equivalent, since by Student’s t-test at 95% confidence level, 
the slope is not significantly different from 1 and the intercept  
1-Phenylpiperazine (B) 8.75 (0.02) 9 8.33 (0.02) 8.41 (0.07) 
N,N-dimethyl-N-benzylamine (B) 8.95 (0.04) 11 8.64 (0.04) 8.76 (0.05) 
3-Chlorophenol (A) 9.04 (0.01) 16  8.73 (0.06) 
Diphenhydramine (B) 9.08 (0.02) 15 8.855 8.83 (0.06) 
4-Bromophenol (A) 9.28 (0.01) 27  9.01 (0.05) 
Imipramine (B) 9.37 (0.02) 17 9.2334 9.25 (0.05) 
Propranolol (B) 9.47 (0.00) 23 9.1732 9.24 (0.08) 
1-Aminoethylbenzene (B) 9.52 (0.01) 11  9.34 (0.10) 
Paracetamol (A) 9.58 (0.02) 11 9.6535 9.31 (0.03) 
Ephedrine (B) 9.72 (0.02) 12 9.12 (0.01) 9.27 (0.04) 
Phenol (A) 9.89 (0.01) 13 9.83 (0.01) 9.54 (0.06) 
Nortriptyline (B) 10.08 (0.01) 5  9.79 (0.04) 
Fig. 1 pKa values at 37 ºC obtained through the IS-CE method vs. the 
reference potentiometric ones. Solid line has an ordinate of 0 and a 
slope of 1. 
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from 0. Thus, the pKa values obtained follow a variation of 
acidity close to the reference one (slope one) and show a 
similar accuracy (intercept zero). However, for a best 
anchoring of the CE data to the potentiometric pKa scale, the 
differences between IS-CE and reference values have been 
calculated for each compound (pKa,Ref – pKa,IS-CE raw), obtaining 
an average difference of -0.063 units (which would correspond 
to the intercept of the line of slope one). Then, the 
electrophoretic data has been corrected by this value to obtain 
the final values presented in Table 1. The correlation between 
the IS-CE measured and reference potentiometric values is 
presented in Figure 1. This set of final pKa values can be used 
for determination of the pKa at 37 ºC of new compounds 
through the IS-CE method. 
 
Determination of pKa at 37 ºC of polyprotic drugs through the IS-
CE method. 
The method has been applied to the determination of acidity 
constants of seven polyprotic drugs. The selected drugs are of 
different nature and show a wide range of acid-base 
functionalities. Their structures are plotted in Figure 2. 
Although these molecules show multiple acid-base groups, 
only those pKa values ranging between 2 and 11 can be 
determined through electrophoretic methods. 
In order to apply the IS-CE method, a first estimation of the pKa 
values of the drugs is needed. This can be easily done through 
estimation software, such as ACD/Percepta.36 This information 
allows the selection of the most appropriate standards (those 
Then, mixtures of the drug with each of the standards have 
been done, and electrophoretic runs performed. Effective 
mobilities have been measured at least in three different 
buffers (normally differing in 0.5 pH units) for each drug-
internal standard pair. Additionally, actual ionic mobilities of 
the internal standards have also been determined to calculate 
the real pH value inside the capillary. When possible, actual 
ionic mobilities of the pure species of drug compounds have 
been measured too. To decide whether actual ionic mobilities 
of the drugs could be experimentally determined, the 
estimated pKa values at 25 ºC were used. In case that two 
consecutive pKas were separated enough (for instance the case 
of procainamide) or the pKa of the most charged species was 
not at very extreme pH values (like cephalexin) the 
experimental determination of the actual ionic mobilities was 
done. Otherwise, they have been calculated in the fitting 
process. Once the real pH inside the capillary is known, the 
mobility vs. pH curve for the drugs can be plotted. Equation 6 
is then fitted to experimental points in order to obtain the pKa 
values. Figure 2 shows the different curves, and Table 2 the 
results obtained for the selected drugs together with the 
statistics of the fits (R2 is the determination coefficient, SD the 
standard error of the fit, and F the Fisher F parameter). pKa 
values have been corrected using the Debye-Hückel equation 
(eq. 5) for 50 mM ionic strength, so that values given 
correspond to thermodynamic quantities.
 
 
Fig. 2 Mobility vs. pH profiles of the polyprotic drugs. Dots indicate the experimental points and the curves the fit of Eq. 6 to 
experimental data. Dashed lines indicate the experimentally measured mobilities. (a) ampicillin; (b) labetalol; (c) procainamide; 
(d) quinine; (e) cephalexin; (f) cefadroxil; (g) tetracycline. 
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Table 2 pKa values at 37 ºC for the polyprotic drugs determined through the IS-CE method. Standard deviation is shown in 
parentheses. 
Drug Acid-base group pKa  ion x 109 a zb Statistics of the fit 
     R2 SD F 
Ampicillin A (carboxylic acid) 2.9 (0.1) 15 (1) +1 0.9969 0.90 318 
 B (prim. amine) 6.9 (0.1) -18 (2) -1    
Labetalol A (phenol) 7.26 (0.03) 15.3 (0.4) +1 0.9999 0.14 9980 
 B (second. amine) 9.35 (0.01) -16.7 (0.2) -1    
Procainamide B (aniline) 2.70 (0.05) 38.2 (0.6) +2 0.9987 0.38 2415 
 B (tert. amine) 9.33 (0.02) 18.9c +1    
Quinine B (heterocycle) 4.31 (0.03) 38.0c +2 0.9992 0.30 2634 
 B (second. amine) 8.44 (0.03) 17.5 (0.3) +1    
Cefalexin A (carboxylic acid) 2.53 (0.06) 19.4 (0.9) +1 0.9985 0.49 1305 
 B (prim. amine) 7.01 (0.04) -16.0c -1    
Cefadroxil A (carboxylic acid) 2.30 (0.08) 21 (2) +1 0.9990 0.63 1236 
 B (prim. amine) 7.07 (0.08) -15 (1) -1    
 A (phenol) 9.8 (0.2) -29.1 (0.9) -2    
Tetracycline A (phenol) 3.19 (0.03) 17.7 (0.4) +1 0.9996 0.25 4344 
 A (phenol) 7.03 (0.05) -9.8 (0.4) -1    
 B (tert. amine) 9.5 (0.1) -14.6c -2    
a actual ionic mobility, in m2·V-1·s-1; b charge number of the protonated or dissociated forms of the drug; c directly measured
Electrophoretic data of the determinations is presented in 
Tables SI-1 to SI-7 of the supplementary information. 
Two different pKa values could be determined for all 
compounds, and three in case of cefadroxil and tetracycline. 
Statistical analysis shows that the fits of equation 6 to 
experimental data have coefficient of determination close to 1, 
and in general, low standard deviations associated with the 
pKa values. However, this is usual in fits with a limited number 
of experimental points, especially if the actual ionic mobilities 
are also estimated. The highest standard deviation value 
corresponds to the third pKa of cefadroxil and is caused by the 
small variation of mobility with pH when changing from the 
monocharged to the dicharged negative species of cefadroxil. 
In the Table 2 are also indicated the acid-base groups 
associated to the pKa value. In the studied pH range 
procainamide and quinine are diprotic bases. Ampicillin, 
labetalol and cefalexin behave as zwitterionic compounds. 
Note that the only difference between cefalexin and cefadroxil 
is an extra phenolic group in cefadroxil (pKa3). There is very 
good agreement between the pKa1 and pKa2 of both 
compounds, which correspond to identical acid-base moieties. 
Finally, tetracycline is a polyprotic compound with many acid-
base groups. According to our data, it behaves as a triprotic 
compound in the pH range studied. A tentative assignation of 
the pKa values according to ACD/Percepta software indicates 
that the first pKa would belong to the phenolic group located in 
the amide ring, the second pKa to the phenolic group located 
in the following aromatic ring, and the third pKa, in the basic 
pH region, would belong to the tertiary amine.  
As commented in the previous section, there is relatively few 
data related to pKa values of drugs, especially polyprotic ones, 
determined at 37 ºC. From the seven drugs studied in this 
work we could only find the pKa values of labetalol for 
comparison. They were determined potentiometrically by 
Avdeef et al.32 in a 0.2M ionic strength media, and their values 
are 7.25 ± 0.01 and 9.00 ± 0.01. In order to compare our 
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results to the ones obtained in the literature, we have 
corrected the values from Avdeef et al. by the activity 
coefficients, obtaining pKa values of 7.25 and 9.28, totally in 
accordance with the values obtained through the IS-CE 
method. 
Conclusions 
This work provides a set of internal standards for the high 
throughput determination of pKa values of drugs at the 
biorelevant temperature of 37 ºC. The IS-CE method has 
several advantages over other methods of pKa determination, 
but in this case it is of especial relevance that external 
measurement of the exact pH of the electrophoretic buffers 
and the pH electrode calibration at 37 ºC can be avoided. 
Accurate results can be obtained with only few electrophoretic 
runs. Comparison of the pKa values at 25 ºC to the ones at 37 
ºC for the set of internal standards indicates that in general 
pKa decreases when temperature increase, although the 
magnitude of the change does not follow a general trend, but 
depends on the nature of the compound evaluated. The 
method has been applied successfully to the determination of 
pKa values of polyprotic drugs, and very good accordance with 
available reference data has been observed.  
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